AG
JAZZ icon

Aperio Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aperio Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.62M Buy
21,953
+599
+3% +$89.2K 0.01% 966
2020
Q3 		$3.04M Sell
21,354
-1,712
-7% -$212K 0.01% 921
2020
Q2 		$2.54M Sell
23,066
-5,964
-21% -$660K 0.01% 1001
2020
Q1 		$2.9M Sell
29,030
-2,276
-7% -$294K 0.01% 860
2019
Q4 		$4.67M Sell
31,306
-7,223
-19% -$983K 0.02% 758
2019
Q3 		$4.94M Sell
38,529
-144
-0.4% -$19.3K 0.02% 714
2019
Q2 		$5.51M Buy
38,673
+14,434
+60% +$1.94M 0.02% 677
2019
Q1 		$3.46M Buy
24,239
+8,132
+50% +$1.06M 0.02% 816
2018
Q4 		$2M Buy
16,107
+4,451
+38% +$660K 0.01% 988
2018
Q3 		$1.96M Buy
11,656
+587
+5% +$101K 0.01% 1073
2018
Q2 		$1.91M Buy
11,069
+1,787
+19% +$292K 0.01% 1051
2018
Q1 		$1.4M Sell
9,282
-5,773
-38% -$847K 0.01% 1147
2017
Q4 		$2.03M Buy
15,055
+9,073
+152% +$1.26M 0.01% 978
2017
Q3 		$875K Sell
5,982
-135
-2% -$20.4K ﹤0.01% 1350
2017
Q2 		$951K Sell
6,117
-513
-8% -$78.4K 0.01% 1262
2017
Q1 		$962K Buy
6,630
+122
+2% +$15.9K 0.01% 1190
2016
Q4 		$709K Sell
6,508
-7,613
-54% -$848K 0.01% 1314
2016
Q3 		$1.72M Sell
14,121
-5,671
-29% -$764K 0.01% 894
2016
Q2 		$2.8M Buy
19,792
+1,271
+7% +$187K 0.02% 691
2016
Q1 		$2.42M Buy
18,521
+4,092
+28% +$509K 0.02% 713
2015
Q4 		$2.03M Buy
14,429
+7,620
+112% +$1.06M 0.02% 749
2015
Q3 		$904K Sell
6,809
-427
-6% -$73.5K 0.01% 1017
2015
Q2 		$1.27M Buy
7,236
+2,712
+60% +$487K 0.01% 877
2015
Q1 		$782K Buy
4,524
+1,074
+31% +$184K 0.01% 1048
2014
Q4 		$565K Buy
3,450
+470
+16% +$78K 0.01% 1158
2014
Q3 		$478K Buy
2,980
+475
+19% +$73K 0.01% 1162
2014
Q2 		$368K Buy
2,505
+617
+33% +$85.6K 0.01% 1278
2014
Q1 		$262K Buy
+1,888
New +$284K ﹤0.01% 1713
2013
Q4 		– Hold
0
– – – 1670

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aperio Group's JAZZ Position: Q4 2020 in Review

Aperio Group increased its Jazz Pharmaceuticals (JAZZ) stake by 2.8% in Q4 2020, buying an estimated $89.2K and bringing the position to 21,953 shares worth $3.62M. The position accounts for 0.01% of the portfolio, ranked #966.

Aperio Group first reported a position in JAZZ in Q1 2014 and has held it in 28 quarters since. The position peaked at $5.51M in Q2 2019. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

  • Aperio Group held 21,953 shares of Jazz Pharmaceuticals worth $3.62M as of Q4 2020.
  • Aperio Group bought 599 Jazz Pharmaceuticals shares in Q4 2020, an estimated $89.2K.
  • Jazz Pharmaceuticals made up 0.01% of Aperio Group's portfolio in Q4 2020, its #966 holding.
  • Aperio Group first reported a position in Jazz Pharmaceuticals in Q1 2014 and has held it in 28 quarters since.
  • Aperio Group's Jazz Pharmaceuticals position peaked at $5.51M in Q2 2019.
  • 437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.